Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En fase 2b klinisk undersøgelse af YN001 hos voksne med koronar aterosklerose (PURIFY-TIMI 81)

3. november 2026 opdateret af: Beijing Inno Medicine Co., Ltd.

En randomiseret, multicentrisk, dobbeltblind, parallel, placebokontrolleret fase 2b klinisk undersøgelse for at evaluere effektiviteten og sikkerheden af YN001 hos voksne med koronar aterosklerose

This study is designed to evaluate the efficacy and safety of intravenously administered YN001 in patients diagnosed with coronary atherosclerosis, who are receiving background therapy for cardiovascular (CV) risk factors management.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This is a multinational, multicenter, randomized, parallel, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of intravenously administered YN001 compared with placebo in participants with coronary atherosclerosis who are receiving background therapy for CV risk factors management.

A total of 456 participants are expected to be enrolled. The study will consist of a maximum 12-week screening/Baseline period, followed by a 12-week blinded treatment period, a 30-day safety follow-up, and a long-term follow-up period through Week 96 (approximately 2 years after randomization).

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

456

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

    • New South Wales
      • Penrith, New South Wales, Australien, 2750
        • Rekruttering
        • Cannopy Clinical Research
        • Kontakt:
    • Queensland
      • Brisbane, Queensland, Australien, 4064
        • Rekruttering
        • Core Research Group Pty Ltd.
        • Kontakt:
    • Victoria
      • Altona N., Victoria, Australien, 3025
        • Rekruttering
        • Canopy Clinical Research
        • Kontakt:
    • Manitoba
      • Winnipeg, Manitoba, Canada, R2H 2A6
        • Ikke rekrutterer endnu
        • St. Boniface Hospital
        • Kontakt:
    • Ontario
      • London, Ontario, Canada, N5A 5A5
        • Ikke rekrutterer endnu
        • London Health Sciences Centre
        • Kontakt:
      • North York, Ontario, Canada, M6B 3H7
        • Ikke rekrutterer endnu
        • North York Diagnostic and Cardiac Centre
        • Kontakt:
      • Toronto, Ontario, Canada, M5B 1W8
        • Ikke rekrutterer endnu
        • St. Michael's Hospital
        • Kontakt:
      • Vaughan, Ontario, Canada, L6A 4N9
        • Ikke rekrutterer endnu
        • Cardiac Clinic
        • Kontakt:
    • Toronto
      • Toronto, Toronto, Canada, M5G 2N2
        • Ikke rekrutterer endnu
        • Toronto General Hospital - University Health Network
        • Kontakt:
    • Alabama
      • Huntsville, Alabama, Forenede Stater, 35801-4312
        • Rekruttering
        • Heart Center Research, LLC
        • Kontakt:
    • California
      • Covina, California, Forenede Stater, 91740
      • Lincoln, California, Forenede Stater, 95648
        • Ikke rekrutterer endnu
        • Clinical Trials Research
        • Kontakt:
      • Los Alamitos, California, Forenede Stater, 90720
        • Ikke rekrutterer endnu
        • University of California Irvine Medical Center - Cardiovascular Center
        • Kontakt:
      • Stanford, California, Forenede Stater, 94305-2200
        • Ikke rekrutterer endnu
        • Stanford Health Care General Cardiology
        • Kontakt:
      • Torrance, California, Forenede Stater, 90502-2006
        • Rekruttering
        • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
        • Kontakt:
    • Florida
      • Boca Raton, Florida, Forenede Stater, 33434
        • Ikke rekrutterer endnu
        • Flourish Research - Boca Raton
        • Kontakt:
      • Hialeah, Florida, Forenede Stater, 33016-1895
        • Rekruttering
        • New Generation of Medical Research, LLC.
        • Kontakt:
      • St. Petersburg, Florida, Forenede Stater, 33709
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30303-3049
        • Ikke rekrutterer endnu
        • Emory Healthcare-Emory Heart & Vascular Center - Executive Park
        • Kontakt:
    • Idaho
      • Meridian, Idaho, Forenede Stater, 83642
        • Ikke rekrutterer endnu
        • St. Luke's Clinic - Idaho Cardiology Associates
        • Kontakt:
    • Illinois
      • Springfield, Illinois, Forenede Stater, 62781
        • Ikke rekrutterer endnu
        • Southern Illinois University School of Medicine
        • Kontakt:
    • Kansas
      • Overland Park, Kansas, Forenede Stater, 66211-1215
        • Rekruttering
        • Midwest Heart & Vascular Specialists, LLC
        • Kontakt:
    • Missouri
      • St Louis, Missouri, Forenede Stater, 63110-1032
        • Rekruttering
        • WU School of Medicine - (CAM) - Heart and Vascular Center
        • Kontakt:
    • North Carolina
      • Raleigh, North Carolina, Forenede Stater, 27607
        • Ikke rekrutterer endnu
        • NC Heart and Vascular Research, LLC
        • Kontakt:
      • Winston-Salem, North Carolina, Forenede Stater, 27104-3520
        • Ikke rekrutterer endnu
        • Javara Inc. - Wake Forest University Health Sciences
        • Kontakt:
    • Ohio
      • Cincinnati, Ohio, Forenede Stater, 45219
    • Oklahoma
      • Oklahoma City, Oklahoma, Forenede Stater, 73135
        • Ikke rekrutterer endnu
        • South Oklahoma Heart Research, LLC
        • Kontakt:
    • Pennsylvania
      • Camp Hill, Pennsylvania, Forenede Stater, 17011
        • Rekruttering
        • Capital Area Research, LLC - Camp Hill
        • Kontakt:
    • Texas
      • Amarillo, Texas, Forenede Stater, 79106
        • Rekruttering
        • PharmaTex Research, LLC
        • Kontakt:
      • Carrollton, Texas, Forenede Stater, 75010
        • Ikke rekrutterer endnu
        • Pulse Care Heart and Vascular
        • Kontakt:
      • Tomball, Texas, Forenede Stater, 77375
    • An
      • Hefei, An, Kina, 230022
        • Rekruttering
        • The First Affiliated Hospital of Anhui Medical Unversity
        • Kontakt:
          • Jianlong Wang, MD
          • Telefonnummer: 0086-13681292304
          • E-mail: Wjlmll@sina.com
    • Anhui
      • Hefei, Anhui, Kina, 230001
        • Rekruttering
        • Anhui Provincial Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Kangyu Chen, MD
        • Underforsker:
          • Chao Gao, MD
    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina, 100035
        • Rekruttering
        • Beijing Jishuitan Hospital
        • Ledende efterforsker:
          • Wei Liu, MD
        • Kontakt:
          • Qingwei Ji, MD
          • Telefonnummer: 0086 18376642655
          • E-mail: jqwl24@163.cou
        • Ledende efterforsker:
          • Qingwei Ji, MD
      • Beijing, Beijing Municipality, Kina, 100029
        • Rekruttering
        • Anzhen Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Yuyang Liu, MD
      • Beijing, Beijing Municipality, Kina, 101100
        • Ikke rekrutterer endnu
        • Beijing Luhe Hospital
        • Kontakt:
    • Fujian
      • Fuzhou, Fujian, Kina, 350001
        • Rekruttering
        • Fujian Medical University Union Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Mingfang Ye, MD
        • Underforsker:
          • Zhaoyang Chen, MD
    • Gansu
      • Lanzhou, Gansu, Kina, 730030
        • Rekruttering
        • The Second Hospital & Clinical Medical School Lanzhou University
        • Kontakt:
    • Guangdong
      • Guangzhou, Guangdong, Kina, 510080
    • Heilongjiang
      • Daqing, Heilongjiang, Kina, 163316
        • Rekruttering
        • Daqing People's Hospital
        • Kontakt:
      • Harbin, Heilongjiang, Kina, 150001
        • Rekruttering
        • The First Affiliated Hospital of Harbin Medical University
        • Kontakt:
        • Ledende efterforsker:
          • Lu Fu, MD
        • Ledende efterforsker:
          • Yongtai Gong, MD
    • Hubei
      • Wuhan, Hubei, Kina, 430071
        • Rekruttering
        • Zhongnan Hospital of Wuhan University
        • Kontakt:
        • Ledende efterforsker:
          • Xiaorong Hu, MD
    • Hunan
      • Changsha, Hunan, Kina, 410008
        • Rekruttering
        • The Second Xiangya Hospital fo Central South University
        • Kontakt:
    • Jilin
      • Changchun, Jilin, Kina, 130033
        • Rekruttering
        • The First Hospital of Jilin University
        • Ledende efterforsker:
          • Qian Tong, MD
        • Kontakt:
    • Liaoning
      • Shenyang, Liaoning, Kina, 110015
        • Rekruttering
        • The People's Hospital of Liaoning Province
        • Ledende efterforsker:
          • Ying Liu, MD
        • Kontakt:
    • Shaanxi
      • Xi'an, Shaanxi, Kina, 710068
        • Rekruttering
        • Shaanxi Provincial People's Hospital
        • Kontakt:
    • Shandong
      • Jinan, Shandong, Kina
        • Rekruttering
        • Central Hospital Affiliated to Shandong First Medicial University
        • Kontakt:
          • Guohai Su, MD
          • Telefonnummer: 0086 19953193319
          • E-mail: gttstg@163.com
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kina, 200032
        • Rekruttering
        • Fudan University-Zhongshan Hospital
        • Ledende efterforsker:
          • Junbo Ge, MD
        • Kontakt:
        • Underforsker:
          • Yuxiang Dai, MD
      • Shanghai, Shanghai Municipality, Kina, 200001
        • Rekruttering
        • Renji Hospital Shanghai Jiaotong University school of medicine
        • Kontakt:
        • Ledende efterforsker:
          • Jun Bu, MD
    • Sichuan
      • Chengdu, Sichuan, Kina, 610041
        • Rekruttering
        • West China Hospital of Sichuan University
        • Kontakt:
        • Ledende efterforsker:
          • Yong He, MD
      • Chengdu, Sichuan, Kina, 610072
        • Rekruttering
        • Sichuan Provincial People's Hospital
        • Kontakt:
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Kina, 300211
        • Rekruttering
        • The Second Hospital of Tianjin Medical University
        • Kontakt:
        • Ledende efterforsker:
          • Tong Liu, MD
      • Tianjin, Tianjin Municipality, Kina, 300121
        • Rekruttering
        • Tianjin People's Hospital
        • Ledende efterforsker:
          • Zhuhua Yao, MD
        • Kontakt:
    • Zhejiang
      • Hangzhou, Zhejiang, Kina, 310006
        • Rekruttering
        • Zhejiang Provincial People's Hospital
        • Kontakt:
      • Suzhou, Zhejiang, Kina, 215006
        • Rekruttering
        • The First Affiliated Hospital of Soochow University
        • Kontakt:
      • Wenzhou, Zhejiang, Kina, 325000
        • Rekruttering
        • The 2nd Affiliated Hospital and Yuying Children's Hospital of WMU
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 80 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Fully understands the purposes, features, and methods of the study and the possible adverse reactions, and is voluntarily willing to participate in the study, and signs the informed consent form (ICF) before performing any study-specific assessment.
  2. Male or female participants between 18 and 80 years (inclusive, at the time of signing the ICF).
  3. Participants must satisfy either of the following criteria:

1) Have clinically evident atherosclerotic CV disease (ASCVD) 2) Meet at least two of the following criteria at screening/baseline, as evidenced by:

  1. A history of Type 2 diabetes requiring treatment with medication,

  2. Aged > 55 years (women) or > 50 years (men),

  3. 2 or more of the following atherosclerosis risk factors:

    • Current cigarette smoker

    • Hypertension

    • Estimated glomerular filtration rate (eGFR) 45 to 60 ml/min/1.73m2

      4. Known coronary atherosclerosis as evidenced through coronary angiography or CCTA. The following criteria must be met on the core lab CCTA interpretation for the patient to be enrolled: at least one epicardial coronary artery with a lumen stenosis of 25% to 69%, total coronary NCPV is at least 75 mm3, Detectable low-attenuation composition in one or more individual plaques.

      5. Female participants must be non-pregnant and non-lactating

      6. Willing and able to comply with the requirements of protocol to the best of the participant's and investigator's knowledge.

Exclusion Criteria:

  1. Prior treatment with other investigational drug(s) within 30 days or 5 half-lives, whichever is longer, prior to randomization.
  2. Previously received YN001.
  3. Any type of vaccination within 4 weeks prior to randomization, or any planned vaccination during the study treatment period
  4. Contraindication for CCTA
  5. 3 major epicardial coronary arteries with ≥ 70% or left main ≥50% stenosis.
  6. Acute MI that occurred within 4 weeks prior to randomization.
  7. PCI performed within 2 weeks prior to randomization or PCI is required or planned during study treatment based on clinical indication for revascularization.
  8. Clinically evident stroke or transient ischemic attack (TIA) within 6 months prior to randomization.
  9. Relapse and highly symptomatic arrhythmia uncontrolled by drugs within the past 3 months.
  10. Prior coronary artery bypass graft (CABG), aortic root surgery with coronary reimplantation, left ventricular assist device (LVAD) placement, surgical aortic valve replacement (SAVR), transcatheter aortic valve replacement (TAVR), or heart transplantation, or a plan to undergo these procedures (CABG, aortic root surgery with coronary reimplantation, LVAD placement, SAVR, TAVR, or heart transplantation) during the study.
  11. New York Heart Association class III or IV or last known left ventricular ejection fraction (LVEF) was <40%.
  12. Carotid endarterectomy or stenting, peripheral arterial revascularization, or abdominal aortic aneurysm repair within 4 weeks prior to randomization.
  13. History of myopathy or myositis, or susceptibility to myopathy/rhabdomyolysis (e.g., family history of hereditary myopathy, etc.).
  14. History of severe myalgia attributed to statin therapy or other significant concern about statin side effects.
  15. Known gastrointestinal ulcers, inflammatory bowel disease, or gastrointestinal/rectal bleeding within 6 months prior to randomization.
  16. Evidence of unresolved major diseases 2 weeks prior to randomization or planned major surgery during the study that, in the investigator's judgement, may interfere with the investigational product administration or trial assessments.
  17. Presenting with history of malignancy (except in participants who have been disease-free >5 years; or whose only malignancy has been basal or squamous cell skin carcinoma).
  18. Presence of any type of autoimmune disease.
  19. Allergy to multiple foods or drugs or known sensitivity to any components to be administered during dosing.
  20. Life expectancy is less than 1 year.
  21. Systolic blood pressure of ≥ 160 mmHg at final screening despite antihypertensive therapy.
  22. Triglycerides ≥ 400 mg/dL (4.5 mmol/L) at final screening.
  23. LDL-C > 100 mg/dL (2.6 mmol/L) at final screening.
  24. Active liver disease or hepatic dysfunction defined by any of alanine aminotransaminase (ALT), aspartate aminotransferase (AST), > 3 times upper limit of normal (ULN), or total bilirubin > 2 times ULN at final screening.
  25. Presence of renal dysfunction, defined by eGFR < 45 ml/min/1.73m2.
  26. Untreated or inadequately treated hypothyroidism.
  27. Poorly controlled Type 2 diabetes mellitus.
  28. A positive hepatitis B surface antigen (HBsAg), or positive antibody against hepatitis C virus (anti-HCV) or human immunodeficiency virus (anti-HIV), or positive treponema pallidum antibody (TP-Ab).
  29. Presence of any other diseases or conditions (apart from those outlined above) that, in the opinion of the investigator, would make it unsuitable for the participant to participate in this study.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Dose 1 YN001/Placebo 40mg

Dose 1 YN001/Placobo 40mg will be administrated intravenously weekly

Dose 1 YN001/Placebo 40mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total.

Eksperimentel: Dose 2 YN001/Placebo 20mg

Dose 2 YN001/Placebo 20mg will be administrated intravenously weekly

YN001/Placebo 20mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total.

Placebo komparator: Dose 3 YN001/Placebo 0mg

Dose 3 YN001/Placebo 0mg will be administrated intravenously weekly

YN001/Placebo 0mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Relative change from baseline in coronary NCPV at Week 13
Tidsramme: Baseline to Week 13

Relative change in coronary NCPV from baseline to Week 13 as determined by coronary computed tomography angiography (CCTA)

Baseline to Week 13

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Absolute change from baseline in carotid intima-media thickness (IMT) at Week 13
Tidsramme: From baseline to Week 13

Absolute change in carotid IMT from baseline to Week 13 as determined by carotid ultrasound.

From baseline to Week 13
Absolute change from baseline in carotid intima-media thickness (IMT) at Week 9
Tidsramme: From baseline to Week 9

Absolute change from baseline in carotid intima-media thickness (IMT) at Week 9

From baseline to Week 9
Relative change from baseline in carotid intima-media thickness (IMT) at Week 13
Tidsramme: From baseline to Week 13

Relative change in carotid IMT from baseline to Week 13 as determined by carotid ultrasound

From baseline to Week 13
Relative change in the maximum thickness and area of carotid plaque at Week 9, and Week 13
Tidsramme: From baseline to Week 9 and Week 13

Relative change in the maximum thickness and area of carotid plaque from baseline to Week 9, and Week 13 as determined by carotid ultrasound

From baseline to Week 9 and Week 13
Relative change in coronary Percent Atheroma Volume (PAV) at Week 13
Tidsramme: From baseline to Week 13

Relative change in coronary Percent Atheroma Volume (PAV) from baseline to Week 13 as determined by CCTA

From baseline to Week 13
Relative change in coronary Low Attenuation Plaque Volume(LAPV) at Week 13
Tidsramme: From baseline to week 13

Relative change in coronary LAPV from baseline to Week 13 as determined by CCTA.

From baseline to week 13
Relative changes in coronary NCPV, PAV, TAV, and LAPV from baseline at 48 week
Tidsramme: From baseline to week 48

Relative changes in coronary NCPV, PAV, TAV, and LAPV from baseline to Week 48 as determined by CCTA

From baseline to week 48
Absolute change in coronary NCPV at week 13 and week 48
Tidsramme: From baseline to week 13 and week 48

Absolute change in coronary NCPV from baseline to Week 13 and Week 48 as determined by CCTA

From baseline to week 13 and week 48
Time to First Occurrence of Any Component of the Major Adverse Cardiac Event (MACE)
Tidsramme: From randomization to Week 96

Time to the first occurrence of the MACE, composite of CV death, myocardial infarction (MI), ischemic stroke, urgent coronary revascularization, or hospitalization for unstable angina

From randomization to Week 96
The safety profile of YN001
Tidsramme: From baseline to Week 13

Incidence of treatment emergent adverse event (TEAE)/serious adverse event (SAE)/adverse event of special interest (AESI)

From baseline to Week 13
Immunogenicity (ADA) analysis
Tidsramme: From baseline to Week 13

Incidence of anti-drug antibodies (ADA) formation

From baseline to Week 13
Immunogenicity (APA) analysis
Tidsramme: From baseline to Week 17

Incidence of anti-PEG antibodies (APA) formation

From baseline to Week 17
YN001 concentrations analysis in plasma
Tidsramme: From baseline to Week 13

Sparse blood samples will be collected, and these concentrations are intended to be pooled with other studies to develop/update pharmacometric models

From baseline to Week 13

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Studieleder: Ying Chen, PhD, Beijing Inno Medicine Co., Ltd.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

31. juli 2026

Primær færdiggørelse (Anslået)

31. juli 2027

Studieafslutning (Anslået)

31. marts 2029

Datoer for studieregistrering

Først indsendt

2. april 2026

Først indsendt, der opfyldte QC-kriterier

2. april 2026

Først opslået (Faktiske)

9. april 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

5. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

3. november 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • YN001-203
  • IND 157167 (Registry Identifier: Beijing Inno Medicine Co., Ltd.)

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .